Two specific molecules, miR-30e-3p and miR-181a-5p, inside stem cell vesicles are responsible for blocking two key inflammatory pathways in the aging brain; removing them makes the treatment...
Claim Context
In aged mice, the therapeutic effects of intranasal hiPSC-NSC-EVs on NLRP3 inflammasome suppression are mediated primarily by miR-30e-3p, and on cGAS-STING pathway suppression by miR-181a-5p, as depletion of these miRNAs abolishes the anti-inflammatory effects.
“In contrast, adding hiPSC-NSC-EVs that are depleted of miR-30e-3p (knockdown EVs [KD-EVs]) did not reduce IL-1β and IL-18 levels compared to the nigericin alone group (p > 0.05)... In contrast, adding hiPSC-NSC-EVs that are depleted of miR-181a-5p (KD-EVs) did not reduce Lucia luciferase activity...”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether miR-30e-3p and miR-181a-5p are consistently the dominant mediators of NLRP3 and STING suppression across different EV sources and aging models.
A systematic review and meta-analysis of all published studies using miRNA-depleted EVs from neural stem cells to treat aged rodents, measuring NLRP3 and STING pathway inhibition and correlating with miR-30e-3p and miR-181a-5p levels in EV cargo.
That miR-30e-3p and miR-181a-5p are necessary and sufficient for the anti-inflammatory effects of hiPSC-NSC-EVs in aged mice.
A double-blind RCT in 120 aged C57BL/6 mice (18 months), randomized to receive intranasal hiPSC-NSC-EVs, EVs depleted of miR-30e-3p, EVs depleted of miR-181a-5p, EVs depleted of both, or vehicle, with primary outcomes being hippocampal NLRP3-ASC complexes, STING pathway proteins, and cognitive discrimination index at 20.5 months.
Whether the concentration of miR-30e-3p and miR-181a-5p in EVs predicts the magnitude of neuroinflammation reduction in aged mice.
A longitudinal cohort study following 80 aged C57BL/6 mice receiving intranasal hiPSC-NSC-EVs, measuring miR-30e-3p and miR-181a-5p levels in hippocampal tissue at 7 and 21 days post-treatment and correlating with NLRP3, STING, and cognitive outcomes.
Whether mice with low endogenous miR-30e-3p or miR-181a-5p expression show reduced response to hiPSC-NSC-EVs treatment.
A case-control study comparing aged C57BL/6 mice with low hippocampal miR-30e-3p or miR-181a-5p expression (cases) to those with normal expression (controls), matched for age and sex, to determine if hiPSC-NSC-EVs treatment is less effective in cases.
Whether miR-30e-3p and miR-181a-5p levels in EVs correlate with NLRP3 and STING suppression in treated aged mice.
A cross-sectional analysis of 60 aged C57BL/6 mice at 20.5 months, measuring miR-30e-3p and miR-181a-5p levels in hippocampal tissue and correlating with NLRP3-ASC complex density and STING pathway protein levels.